Higher doses produce increased incidence and severity of gastrointestinal symptoms, which explains why clinical protocols use gradual dose escalation starting at 0.25 mg weekly and incrementally increasing every 4 weeks
First discovered in the 1970s by biochemist Dr Loren Pickart, GHK-Cu quickly became known for its regenerative properties, particularly its role in wound healing, tissue repair, and collagen synthesis
There are no major side effects reported, though patients can experience diarrhea and swelling or redness at the injection site
doi: 10.1016/j.cej.2020.124875
Anything that is injected through the skin, that travels to and is released into the muscle, can result in your body retaliating and building an antibody or allergy to whatever substances were injected, such as B12
Furthermore, in another meta-analysis [23], which excluded ELIXA [24] due to fact that lixisenatide is a short-acting GLP-1RA and all participants had acute coronary syndrome, GLP-1RAs were associated with significant reductions in MACE (HR 0.85, 95% CI 0.800.90), cardiovascular death (HR 0.85, 95% CI 0.780.93), stroke (HR 0.81, 95% CI 0.740.90), and myocardial infarction (HR 0.88, 95% CI 0.810.96) (Table 2)
